SISTEMATIC REVIEW : CRISPR-CAS SEBAGAI ALTERNATIF DALAM MENGURANGI RESISTENSI ANTIBIOTIK

Authors

  • Rizatul Hikmah Program Studi Farmasi Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Afifa Dian Safitri Program Studi Farmasi Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Baiq Khaeratinnisa Oktari Program Studi Farmasi Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Muhammad Iqbal Farobbi Program Studi Farmasi Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Baiq Ayu Wulan Maharani Putri Program Studi Farmasi Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram

DOI:

https://doi.org/10.31004/jkt.v5i4.37583

Keywords:

Kata kunci: Antibiotik, CRISPR-Cas, Resistensi

Abstract

Resistensi antibiotik merupakan krisis kesehatan global dengan dampak serius, termasuk peningkatan morbiditas, mortalitas, dan beban ekonomi. Antibiotik konvensional semakin tidak efektif, sehingga diperlukan solusi inovatif. Salah satu teknologi yang dapat digunakan untuk mengatasi masalah ini adalah sistem CRISPR-Cas yang merupakan alat pengeditan genom yang bekerja dengan cara menargetkan dan memanipulasi determinan genetik resistensi pada bakteri. Penelitian ini bertujuan untuk mengevaluasi efektivitas CRISPR-Cas dalam menurunkan resistensi antibiotik pada berbagai bakteri patogen. Desain dalam artikel ini adalah sistematik review. Artikel yang dipilih yaitu artikel yang diterbitkan tahun 2017- 2024, tersedia dalam ful-text, dan sumbernya mencakup jurnal nasional dan internasional. Hasil penelitian menunjukkan bahwa CRISPRCas efektif dalam mengurangi resistensi antibiotik melalui beberapa mekanisme, termasuk pemotongan plasmid pembawa gen resistensi, represi transkripsi gen, dan peningkatan sensitivitas bakteri terhadap antibiotik. Hasil penelitian ini juga menunjukkan bahwa sistem ini mampu mencegah transfer gen horizontal, mengurangi ekspresi gen resistensi, dan menghilangkan plasmid dengan salinan tinggi pada bakteri patogen. Meskipun memiliki potensi besar, tantangan seperti efek off-target dan adaptasi genetik bakteri tetap memerlukan pengembangan lebih lanjut untuk aplikasi klinis yang optimal. Sebagai kesimpulan, teknologi CRISPR-Cas memiliki potensi besar untuk menjadi alternatif dalam terapi resistensi antibiotik, meskipun masih ada beberapa keterbatasan yang memerlukan pengembangan lebih lanjut, terutama terkait dengan tantangan off-target.

References

Chen, S., Liu, H., Liang, W., Hong, L., Zhang, B., Huang, L., Guo, X., & Duan, G. (2019). Insert sequences of CRISPR/Cas system regulate horizontal antibiotic gene transfer in Shigella.

International Journal of Antimicrobial Agents, 53(2), 109–115. https://doi.org/10.1016/j.ijantimicag.2018.09.020

Evans, B. A., Pickerill, E. S., Vyas, V. K., & Bernstein, D. A. (2018). Crispr-mediated genome editing of the human fungal pathogen candida albicans. Journal of Visualized Experiments, 141, 1–8. https://doi.org/10.3791/58764

Junaid, M., Thirapanmethee, K., Khuntayaporn, P., & Chomnawang, M. T. (2023). CRISPR-Based Gene Editing in Acinetobacter baumannii to Combat Antimicrobial Resistance. Pharmaceuticals, 16(7), 1–32. https://doi.org/10.3390/ph16070920

Kang, Y. K., Kwon, K., Ryu, J. S., Lee, H. N., Park, C., & Chung, H. J. (2017). Nonviral Genome Editing

Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and

Antibiotic Resistance. Bioconjugate Chemistry, 28(4). https://doi.org/10.1021/acs.bioconjchem.6b00676

Kippnich, J., Benz, F., Uecker, H., & Baumdicker, F. (2024). Effectiveness of CRISPR-Cas in Sensitizing Bacterial Populations with Plasmid-Encoded Antimicrobial Resistance. BioRxiv, 1–14.

Li, Q., Zhao, P., Li, L., Zhao, H., Shi, L., & Tian, P. (2020). Engineering a CRISPR Interference System To Repress a Class 1 Integron in Escherichia coli. Antimicrobial Agents and Chemotherapy, 64(3), 1–15.

Li, X., Bao, N., Yan, Z., Yuan, X.-Z., Wang, S.-G., & Xia, P.-F. (2022). Tailoring CRISPR-Cas Immunity for the Degradation of Antibiotic Resistance Genes. BioRxiv, 03.

Mahendra, C. (2021). Terapi CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats): Pengenalan untuk Penggunaan Klinis. Cermin Dunia Kedokteran, 48(11), 369–371. https://doi.org/10.55175/cdk.v48i11.1560

Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Aguilar, G. R., Mestrovic, T., Smith, G., Han, C., Hsu, R. L., Chalek, J., Araki, D. T., Chung, E., Raggi, C., Hayoon, A. G., Weaver, N. D., Lindstedt, P. A., Smith, A. E., … Abukhadijah, H. J. (2024). Articles Global burden of bacterial antimicrobial resistance 1990 – 2021?: a systematic analysis with forecasts to 2050. The Lancet, 404, 1199–1226. https://doi.org/10.1016/S0140-6736(24)01867-1

Neo, D. M., Clatworthy, A. E., & Hung, D. T. (2024). A dual-plasmid CRISPR/Cas9-based method for rapid and efficient genetic disruption in Mycobacterium abscessus. Journal of Bacteriology, 206(3), 1–16.

Price, V. J., McBride, S. W., Duerkop, B. A., & Palmer, K. L. (2018). CRISPR-Cas blocks antibiotic resistance plasmid transfer between Enterococcus faecalis strains in the gastrointestinal tract. BioRxiv, 28(2), 1–35.

Selle, K., Fletcher, J. R., Tuson, H., Schmitt, D. S., Mcmillan, L., Vridhambal, G. S., Rivera, A. J., Montgomery, S. A., Fortier, L., Barrangou, R., Theriot, C. M., & Ousterout, D. G. (2020). In Vivo Targeting of Clostridioides difficile Using Phage- Delivered CRISPR-Cas3 Antimicrobials. MBio, 11(2), 1–12.

Sheng, H., Wu, S., Xue, Y., Zhao, W., Caplan, A. B., Hovde, C. J., & Minnich, S. A. (2023). Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance. PLoS ONE, 18(9 September), 1–17. https://doi.org/10.1371/journal.pone.0291520 Siahaan, S., Herman, M. J., & Fitri, N. (2022). Antimicrobial Resistance Situation in Indonesia: A Challenge of Multisector and Global Coordination. Journal of Tropical Medicine, 2022, 1–10. https://doi.org/10.1155/2022/2783300

Soetedjo, R., Alexander, L., & Tobian, N. (2020). Penggunaan Crispr-Cas System Sebagai Solusi Menghadapi Resistensi Antimikroba Pada Bakteri. Essential: Essence of Scientific Medical Journal, 18(2), 33–40. https://doi.org/10.24843/estl.2020.v18.i02.p05

Soliman, M., Said, H. S., El-Mowafy, M., & Barwa, R. (2022). Novel PCR detection of CRISPR/Cas systems in Pseudomonas aeruginosa and its correlation with antibiotic resistance. Applied Microbiology and Biotechnology, 106(21), 7223–7234. https://doi.org/10.1007/s00253-022-121441

Tagliaferri, T. L., Guimarães, N. R., Pereira, M. de P. M., Vilela, L. F. F., Horz, H. P., Santos, S. G. dos, & Mendes, T. A. de O. (2020). Exploring the Potential of CRISPR-Cas9 Under Challenging

Conditions: Facing High-Copy Plasmids and Counteracting Beta-Lactam Resistance in Clinical Strains of Enterobacteriaceae. Frontiers in Microbiology, 11(April), 1–11. https://doi.org/10.3389/fmicb.2020.00578

Tao, S., Chen, H., Li, N., Fang, Y., Zhang, H., Xu, Y., Chen, L., & Liang, W. (2023). Elimination of bla KPC?2-mediated carbapenem resistance in Escherichia coli by CRISPR-Cas9 system. BMC

Microbiology, 23(1), 1–8. https://doi.org/10.1186/s12866-023-03058-7

Uribe, R. V., Rathmer, C., Jahn, L. J., Ellabaan, M. M. H., Li, S. S., & Sommer, M. O. A. (2021). Bacterial resistance to CRISPR-Cas antimicrobials. Scientific Reports, 11(1), 1–9. https://doi.org/10.1038/s41598-021-96735-4

Wang, R., Shu, X., Zhao, H., Xue, Q., Liu, C., Wu, A., Cheng, F., Wang, L., Zhang, Y., Feng, J., Wu, N., & Li, M. (2023). Associate toxin-antitoxin with CRISPR-Cas to kill multidrug-resistant pathogens.

Nature Communications, 14(1), 1–13. https://doi.org/10.1038/s41467-023-37789-y

Wu, X., Zha, J., Koffas, M. A. G., & Dordick, J. S. (2019). Reducing Staphylococcus aureus Resistance to Lysostaphin using CRISPR-dCas9. Biotechnology and Bioengineering, 116(12), 3149–3159. https://doi.org/10.1002/bit.27143

Xu, Y., & Li, Z. (2020). CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Computational and Structural Biotechnology Journal, 18, 2401–2415. https://doi.org/10.1016/j.csbj.2020.08.031

Yao, S., Wei, D., Tang, N., Song, Y., Wang, C., Feng, J., & Zhang, G. (2022). Efficient Suppression of Natural Plasmid-Borne Gene Expression in Carbapenem-Resistant Klebsiella pneumoniae Using a Compact CRISPR Interference System. Antimicrobial Agents and Chemotherapy, 66(11), 1–9.

https://doi.org/10.1128/aac.00890-22

Downloads

Published

2024-12-29

Issue

Vol. 5 No. 4 (2024): DESEMBER 2024

Section

Articles

License

Copyright (c) 2024 Rizatul Hikmah, Afifa Dian Safitri, Baiq Khaeratinnisa Oktari, Muhammad Iqbal Farobbi, Baiq Ayu Wulan Maharani Putri

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).